Apogee Therapeutics
APGE
139 hedge funds and large institutions have $3.52B invested in Apogee Therapeutics in 2024 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 52 increasing their positions, 19 reducing their positions, and 8 closing their positions.
1,231% more call options, than puts
Call options by funds: $4.51M | Put options by funds: $339K
675% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 8
267% more funds holding in top 10
Funds holding in top 10: 3 → 11 (+8)
202% more capital invested
Capital invested by funds: $1.16B → $3.52B (+$2.35B)
174% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 19
64% more funds holding
Funds holding: 85 → 139 (+54)
8.12% more ownership
Funds ownership: 112.31% → 120.43% (+8.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$75.3M |
| 2 |
BlackRock
New York
|
+$50.9M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$50.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$42.3M |
| 5 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$36.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$39M |
| 2 |
O
OrbiMed
New York
|
-$24.4M |
| 3 |
Janus Henderson Group
London,
|
-$20.7M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.3M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$11.2M |
APGE Hedge Fund Activity: Q1 2024 in Review
139 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Apogee Therapeutics (APGE) for Q1 2024, worth a combined $3.52B — up 202% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new APGE positions and 8 closed out — a net gain of 54 holders — while 52 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $75.3M. The largest seller was Fairmount Funds Management, cutting an estimated $39M.
- 139 institutional investors held Apogee Therapeutics (APGE) as of Q1 2024, up from 85 in Q4 2023.
- Funds reported $3.52B of Apogee Therapeutics stock for Q1 2024, up 202% quarter-over-quarter.
- 62 funds opened new Apogee Therapeutics positions in Q1 2024 and 8 closed out, a net change of +54 holders.
- The largest Apogee Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $75.3M added.
- The largest Apogee Therapeutics seller in Q1 2024 was Fairmount Funds Management, an estimated $39M sold.
Based on aggregated 13F filings for Q1 2024.